Simplified within-host and dose-response models of SARS-CoV-2

DOI10.1016/J.JTBI.2023.111447zbMATH Open1518.92168MaRDI QIDQ6174192FDOQ6174192

Authors: Jingsi Xu, Jonathan Carruthers, Thomas Finnie, Ian M. Hall 

Publication date: 14 July 2023

Published in: Journal of Theoretical Biology (Search for Journal in Brave)

Recommendations

• Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: parameter estimates, identifiability, sensitivity and the eclipse phase profile
• Parsimonious models of in-host viral dynamics and immune response
• A mathematical model of within-host COVID-19 dynamics
• Dynamics of SARS-CoV-2 infection model with two modes of transmission and immune response
• The within-host viral kinetics of SARS-CoV-2

zbMATH Keywords

dose-responseSARS-CoV-2within-host models

Mathematics Subject Classification ID

Epidemiology (92D30)

Cites Work

• Title not available (Why is that?)
• Modeling amantadine treatment of influenza A virus in vitro
• Modeling the viral dynamics of SARS-CoV-2 infection

Cited In (10)

• A mathematical model of within-host COVID-19 dynamics
• Why, when and how should exposure be considered at the within-host scale? A modelling contribution to PRRSv infection
• A simple in-host model for COVID-19 with treatments: model prediction and calibration
• Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: parameter estimates, identifiability, sensitivity and the eclipse phase profile
• Modeling identifies variability in SARS-CoV-2 uptake and eclipse phase by infected cells as principal drivers of extreme variability in nasal viral load in the 48 h post infection
• The within-host viral kinetics of SARS-CoV-2
• Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors
• A mechanistic modeling and estimation framework for environmental pathogen surveillance
• Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors
• A model for SARS-CoV-2 infection with treatment

This page was built for publication: Simplified within-host and dose-response models of SARS-CoV-2

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6174192)